

CITATION REPORT

List of articles citing

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel

DOI: 10.1016/s0002-9394(00)00659-0

American Journal of Ophthalmology, 2000, 130, 492-513.

Source: <https://exaly.com/paper-pdf/32012583/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
818	Uveitis in children. 2000 , 8, 251-61		145
817	Ocular manifestations of vasculitis. 2001 , 27, 761-79, vi		26
816	A role for methotrexate in the management of non-infectious orbital inflammatory disease. 2001 , 85, 1220-4		117
815	Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. 2001 , 7, 175-8		7
814	Inflammatory conditions of the eye associated with rheumatic diseases. 2001 , 3, 453-8		23
813	Uveitis associated with childhood rheumatic diseases. 2002 , 14, 542-7		19
812	Immunomodulatory therapy for anterior segment ocular inflammation. 2002 , 2, 429-33		3
811	Birdshot retinochoroidopathy: immunopathogenesis, evaluation, and treatment. 2002 , 15, 343-50, vii		28
810	Immunosuppression in uveitis. 2002 , 15, 395-404, viii		10
809	Corticosteroids in uveitis. 2002 , 15, 389-94		23
808	Bench to bedside: new approaches to the immunotherapy of uveitic disease. 2002 , 21, 273-89		56
807	Management of uveitis in pediatric patients: special considerations. 2002 , 4, 183-9		17
806	Multifocal choroiditis and panuveitis: immunomodulatory therapy. 2002 , 109, 378-83		52
805	Discussion by Douglas A. Jabs, MD, MBA. 2002 , 109, 806-807		13
804	Successful treatment of serpiginous choroiditis with alkylating agents. 2002 , 109, 1506-13		75
803	Management of uveitis: a rheumatologic perspective. 2002 , 46, 309-18		45
802	Die rheumatische Uveitis im Kindesalter. 2002 , 150, 470-476		1

801	Ocular mucous membrane pemphigoid. 2002 , 15, 389-396	5
800	Corticosteroid-induced osteoporosis in patients with uveitis. 2002 , 16, 587-93	13
799	Electroretinograms as an indicator of disease activity in birdshot retinochoroidopathy. 2002 , 240, 601-7	57
798	Orbital inflammation. 2003 , 3, 401-9	11
797	Ocular vasculitis. 2003 , 5, 100-6	3
796	Clinical trials in pediatric uveitis. 2003 , 5, 477-81	3
795	Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. 2003 , 11, 131-9	53
794	Special considerations in the evaluation and management of uveitis in children. <i>American Journal of Ophthalmology</i> , 2003 , 135, 867-78	4-9 82
793	Recent advances in uveitis of juvenile idiopathic arthritis. 2003 , 48, 489-502	83
792	Role of amniotic membrane transplantation for conjunctival reconstruction in ocular-cicatricial pemphigoid. 2003 , 110, 474-80	56
791	Treatment of ocular inflammatory disorders with daclizumab. 2003 , 110, 786-9	83
790	Mycophenolate mofetil for the treatment of scleritis. 2003 , 110, 1750-5	56
789	Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. 2003 , 110, 1744-9	230
788	Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome. 2003 , 110, 1764-9	34
787	Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. 2003 , 21, 283-93	110
786	Methotrexate in inflammatory eye disease. 2003 , 11, 79-82	4
785	Cystoid macular edema in uveitis. 2003 , 11, 29-38	49
784	Systemic management of posterior uveitis. 2003 , 19, 325-43	5

783	Retinal vein occlusion and cardiovascular risk assessment. 2003 , 87, 124	
782	Congenital trichomegaly (Oliver-McFarlane syndrome): a case report with 9 years' follow up. 2003 , 87, 119-20	19
781	Adult orbital xanthogranuloma with periosteal infiltration. 2003 , 87, 120-1	7
780	A randomised controlled trial of written information. 2003 , 87, 124	
779	Visual symptoms in patients on cyclophosphamide may herald sight threatening disease. 2003 , 87, 122-3	6
778	Assessment of endothelium from donor corneas. 2003 , 87, 123	
777	Tacrolimus. 2003 , 87, 121-2	15
776	Eyelid skin adenoid cystic carcinoma: a clinicopathological study of one case simulating sebaceous gland carcinoma. 2003 , 87, 118-9	15
775	Acute keratoconus with perforation in a patient with Down's syndrome. 2003 , 87, 120	18
774	Retinal vasculitis. 2003 , 14, 413-9	54
773	Use of immunosuppressive agents in uveitis. 2003 , 14, 399-412	26
772	New treatments for serpiginous choroiditis. 2003 , 14, 128-31	25
771	Management of the Clinically Inapparent Adrenal Mass. 2004 , 140, 401	1
770	Advance directives, due process, and medical futility. 2004 , 140, 402-3; author reply 404	3
769	Acute renal failure associated with legionellosis. 2004 , 140, 406-7	3
768	Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. 2004 , 122, 845-51	55
767	Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. 2004 , 140, 404-6	152
766	Treatment of ocular inflammation in children. 2004 , 6, 289-301	15

765	Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease. 2004 , 88, 673-80	36
764	Prevalent use of complementary and alternative medicine by patients with inflammatory eye disease. 2004 , 12, 203-14	72
763	Uveitis: a potentially blinding disease. 2004 , 218, 223-36	211
762	Intraocular inflammation in autoimmune diseases. 2004 , 34, 602-9	37
761	Management of uveitis. 2004 , 4, 21-9	10
760	Uveitis en niños. 2004 , 2, 313-318	
759	Mucous membrane pemphigoid and pseudopemphigoid. 2004 , 111, 45-52	143
758	Immunomodulatory medications in uveitis. 2004 , 44, 187-203	13
757	Review of immunosuppressive drug therapy in uveitis. 2004 , 15, 293-8	21
756	Metformin hepatotoxicity. 2004 , 140, W25	15
755	Glaucoma in patients with ocular inflammatory disease. 2005 , 18, 421-30, vii	18
754	Herpes simplex keratitis misdiagnosed as rheumatoid arthritis-related peripheral ulcerative keratitis. 2005 , 24, 1015-7	14
753	The diagnosis and management of anterior scleritis. 2005 , 45, 191-204	38
752	Retinal vasculitis. 2005 , 45, 99-113	21
751	Management of chronic pediatric uveitis. 2005 , 16, 281-8	23
750	Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease. 2005 , 45, 179-89	13
749	Immunosuppression for posterior uveitis. 2005 , 25, 1-18	40
748	Induction of suppressors of cytokine signaling (SOCS) in the retina during experimental autoimmune uveitis (EAU): potential neuroprotective role of SOCS proteins. 2005 , 168, 118-27	29

747	Are we still reluctant to immunosuppress?. 2005 , 33, 1-2	3
746	Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. 2005 , 33, 16-21	24
745	[Strategies for the immunosuppressive therapy of intraocular inflammation]. 2005 , 102, 341-8	0
744	[Intraocular inflammations. A diagnostic and therapeutic challenge]. 2005 , 102, 325-8	0
743	[Uveitis in conjunction with rheumatological diseases in childhood]. 2005 , 102, 463-76	4
742	The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. 2005 , 89, 806-8	52
741	A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. 2005 , 123, 903-12	275
740	Inhibition of experimental autoimmune anterior uveitis by adenovirus-mediated transfer of the interleukin-10 gene. 2005 , 21, 420-8	15
739	Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. 2005 , 16, 1037-46	46
738	Effects of the NF-kappaB inhibitor pyrrolidine dithiocarbamate on experimentally induced autoimmune anterior uveitis. 2005 , 46, 1339-47	37
737	Noninfectious uveitis: a scarcity of randomized clinical trials. 2005 , 123, 682-3	11
736	[Not Available]. 2005 , 1 Suppl 1, S54-60	
735	[News on therapies for uveitis]. 2005 , 28, 556-61	1
734	Therapeutic decision in anterior scleritis: our experience at a tertiary care eye center. 2005 , 28, 1065-9	4
733	Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. 2005 , 13, 335-51	59
732	Clinical features and outcomes of HLA-b27-positive and HLA-B27-negative acute anterior uveitis in a Turkish patient population. 2005 , 13, 367-73	33
731	SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): a potential bio-marker for monitoring response of uveitis patients to Daclizumab therapy. 2005 , 24, 39-46	10
730	Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. 2005 , 112, 764-70	106

729	Mycophenolate mofetil therapy for inflammatory eye disease. 2005 , 112, 1472-7		168
728	Psoriatic uveitis: a distinct clinical entity?. <i>American Journal of Ophthalmology</i> , 2005 , 139, 106-11	4.9	63
727	Birdshot retinochoroidopathy: ocular complications and visual impairment. <i>American Journal of Ophthalmology</i> , 2005 , 140, 45-51	4.9	96
726	Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. <i>American Journal of Ophthalmology</i> , 2005 , 140, 509-16	4.9	2722
725	Vogt-Koyanagi-Harada disease: clinical outcomes. <i>American Journal of Ophthalmology</i> , 2005 , 140, 674-8	4.9	78
724	Management of sight-threatening uveitis: new therapeutic options. 2005 , 65, 497-519		35
723	Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management. 2006 , 23, 535-58		29
722	Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. 2006 , 14, 87-90		79
721	Efficacy of intravenous immunoglobulin treatment in refractory uveitis. 2006 , 14, 367-74		18
720	Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. 2006 , 41, 183-9		29
719	Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results. <i>American Journal of Ophthalmology</i> , 2006 , 141, 218-20	4.9	30
718	The enigma of pars planitis, revisited. <i>American Journal of Ophthalmology</i> , 2006 , 141, 729-30	4.9	7
717	Adalimumab therapy for childhood uveitis. 2006 , 149, 572-5		162
716	Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. 2006 , 113, 1020-7		353
715	Role of electron microscopy in the diagnosis of ocular mucous membrane pemphigoid. 2006 , 113, 1651-6		8
714	Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity. 2006 , 113, 2310-6		77
713	Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. 2006 , 46, 141-64		20
712	Vogt-Koyanagi-Harada disease. 2006 , 46, 111-22		70

711	Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. 2006 , 124, 1012-8	32
710	Ocular complications of childhood rheumatic diseases: uveitis. 2006 , 8, 459-68	9
709	Uveitis. 2006 , 20, 487-505	63
708	Biologic therapies for inflammatory eye disease. 2006 , 34, 365-74	62
707	Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. 2006 , 90, 1481-5	21
706	Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis. 2006 , 14, 233-8	23
705	Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. 2006 , 22, 168-75	22
704	Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. 2006 , 14, 333-9	35
703	Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. 2007 , 46, 736-41	231
702	Mycophenolate mofetil in the treatment of uveitis in children. 2007 , 91, 180-4	74
701	Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis. 2007 , 15, 345-6	13
700	Orbital syndromes. 2007 , 27, 269-87	14
699	Emerging biologics in the treatment of uveitis. 2007 , 3, 781-96	3
698	In vitro diffusion of the immunosuppressant tacrolimus through human and rabbit corneas. 2007 , 23, 146-51	6
697	The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. 2007 , 15, 381-7	39
696	Pediatric rheumatology for the adult rheumatologist II: uveitis in juvenile idiopathic arthritis. 2007 , 13, 205-10	16
695	Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. 2007 , 18, 212-9	22
694	Etanercept monotherapy induces complete resolution of cystoid macular edema in a patient with intermediate uveitis. 2007 , 1, 261-3	4

693	Drug delivery methods for posterior segment disease. 2007 , 18, 235-9		70
692	The use of biologics and other immunosuppressants in the treatment of common inflammatory diseases in neuro-ophthalmology. 2007 , 47, 151-60, x		1
691	Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. 2007 , 27, 399-413		116
690	Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. <i>American Journal of Ophthalmology</i> , 2007 , 143, 840-846	4.9	165
689	Uveitis and Immunological Disorders. 2007 ,		
688	Novel intravitreal fluocinolone acetonide implant in the treatment of chronic noninfectious posterior uveitis. 2007 , 2, 33-44		5
687	Intravitreal toxicity of high-dose etanercept. 2007 , 23, 57-62		17
686	Next-generation calcineurin inhibitors for ophthalmic indications. 2007 , 16, 1525-40		23
685	Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. 2007 , 46, 1161-4		128
684	Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes. 2007 , 48, 3230-8		64
683	Reconsidering treatment options in childhood uveitis. 2007 , 91, 133-4		4
682	Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. 2007 , 56, 647-57		208
681	TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. 2007 , 13, 711-8		657
680	Advances in the diagnosis and immunotherapy for ocular inflammatory disease. 2008 , 30, 145-64		23
679	[Mucous membrane pemphigoid with ocular involvement. Part II: therapy]. 2008 , 105, 405-19		8
678	Loss of visual field among patients with birdshot chorioretinopathy. <i>American Journal of Ophthalmology</i> , 2008 , 145, 23-28	4.9	68
677	Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. <i>American Journal of Ophthalmology</i> , 2008 , 145, 667-675	4.9	35
676	Retrospective review of methotrexate therapy in the treatment of chronic, noninfectious, nonnecrotizing scleritis. <i>American Journal of Ophthalmology</i> , 2008 , 145, 487-492	4.9	25

- 675 Mycophenolate mofetil for the treatment of uveitis. *American Journal of Ophthalmology*, **2008**, 146, 752-60, 760.e1-3 4.9 56
- 674 Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. *American Journal of Ophthalmology*, **2008**, 146, 802-12.e1 10.8 108
- 673 Education in the ophthalmic discipline of uveitis. *American Journal of Ophthalmology*, **2008**, 146, 799-801.4.9 5
- 672 Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. **2008**, 115, 1416-21, 1421.e1 99
- 671 Epidemiology of uveitis. **2008**, 15, 283-4 33
- 670 Mycophenolate mofetil in the treatment of ocular inflammation in ANCA-associated vasculitis. **2008**, 24, 249-54 8
- 669 Adalimumab therapy for refractory uveitis: a pilot study. **2008**, 24, 351-61 89
- 668 Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. **2008**, 15, 47-55 82
- 667 Fluocinolone acetonide for the treatment of uveitis: weighing the balance between local and systemic immunosuppression. **2008**, 126, 1287-9 9
- 666 Anti-inflammatory and immunosuppressive concepts. **2008**, 41, 75-84
- 665 The genetics of Adamantiades-Behcet's disease. **2008**, 23, 73-9 16
- 664 Loss of corneal epithelial stem cell properties in outgrowths from human limbal explants cultured on intact amniotic membrane. **2008**, 3, 329-42 59
- 663 Idiopathic intermediate uveitis in childhood. **2008**, 48, 61-74 17
- 662 Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. **2008**, 28, 1280-8 40
- 661 A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. **2008**, 2, 693-702 17
- 660 Posterior Segment Uveitis. **2008**, 301-315
- 659 Induction of durable remission in ocular inflammatory diseases. **2009**, 19, 118-23 8
- 658 Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease. **2009**, 3, 567-79 5

657	Steroid refractory CD4+ T cells in patients with sight-threatening uveitis. 2009 , 50, 4273-8		20
656	General principles for the treatment of non-infectious uveitis. 2009 , 8, 260-5		6
655	Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection. 2009 , 17, 216-20		9
654	Intravenous daclizumab for recalcitrant ocular inflammatory disease. 2009 , 247, 687-92		26
653	Mycophenolate mofetil therapy in uveitis: analysis of eight cases in a tertiary ophthalmic care centre in India. 2009 , 29, 117-22		6
652	Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. 2009 , 29, 127-33		44
651	Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. 2009 , 89, 238-45		57
650	Methotrexate for ocular inflammatory diseases. 2009 , 116, 2188-98.e1		219
649	Etiology and treatment of macular edema. <i>American Journal of Ophthalmology</i> , 2009 , 147, 11-21.e1	4.9	143
648	Chronic anterior uveitis in children: clinical characteristics and complications. <i>American Journal of Ophthalmology</i> , 2009 , 147, 667-678.e5	4.9	81
647	Ranibizumab for refractory uveitis-related macular edema. <i>American Journal of Ophthalmology</i> , 2009 , 148, 303-309.e2	4.9	63
646	Azathioprine for ocular inflammatory diseases. <i>American Journal of Ophthalmology</i> , 2009 , 148, 500-509.e29		165
645	Scleritis and systemic disease association in a community-based referral practice. <i>American Journal of Ophthalmology</i> , 2009 , 148, 946-50	4.9	53
644	The College of Optometrists in Vision Development checklist related to vision function: expert opinions. 2009 , 80, 688-94		2
643	Glaucoma. 2009 ,		3
642	Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. 2009 , 24, 93-9		40
641	Uveitis II. Tratamiento sistémico. 2009 , 10, 2155-2161		
640	Discontinuous drug combination therapy in autoimmune ocular disorders. 2009 , 87, 340-5		5

639	Infliximab for the treatment of active scleritis. 2009 , 44, e9-e12	41
638	Anti-inflammatory therapy in uveitis. 2009 , 3, 188-94	
637	An update on the cause and treatment of scleritis. 2010 , 21, 463-7	17
636	Vogt-Koyanagi-Harada syndrome: a rheumatologic perspective. 2010 , 5, 255-263	3
635	Current therapeutic approaches to autoimmune chronic uveitis in children. 2010 , 9, 674-83	69
634	Immunomodulatory therapy in uveitis. 2010 , 248-258	
633	Philosophy, Goals, and Approaches to Medical Therapy. 2010 , 76-113	5
632	Update on immunosuppressive therapy for corneal transplantation. 2010 , 50, 113-22	18
631	The dream of biologics in uveitis. 2010 , 128, 632-5	6
630	Clinical features of tuberculous serpiginouslike choroiditis in contrast to classic serpiginous choroiditis. 2010 , 128, 853-8	96
629	Investigation and management of uveitis. 2010 , 341, c4976	40
628	Immune mechanisms of intraocular inflammation. 2010 , 5, 43-58	5
627	Vision- and health-related quality of life in patients with Behçet uveitis. 2010 , 128, 1265-71	29
626	Practical approach to the use of corticosteroids in patients with uveitis. 2010 , 45, 352-8	21
625	Cotton wool spots as an indicator of methotrexate-induced blood dyscrasia. 2010 , 81, 177-80	8
624	Cyclophosphamide for ocular inflammatory diseases. 2010 , 117, 356-65	120
623	Cyclosporine for ocular inflammatory diseases. 2010 , 117, 576-84	176
622	Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. 2010 , 117, 567-75, 575.e1	110

621	Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. 2010 , 117, 1436-41		130
620	HLA typing in uveitis: use and misuse. <i>American Journal of Ophthalmology</i> , 2010 , 149, 189-193.e2	4-9	57
619	Mycophenolate mofetil for ocular inflammation. <i>American Journal of Ophthalmology</i> , 2010 , 149, 423-32.e192	4-9	180
618	The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. <i>American Journal of Ophthalmology</i> , 2010 , 149, 550-561.e10	4-9	133
617	Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. <i>American Journal of Ophthalmology</i> , 2010 , 149, 800-6.e1	4-9	34
616	Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. <i>American Journal of Ophthalmology</i> , 2010 , 150, 534-542.e2	4-9	54
615	Scleral thickness following fluocinolone acetonide implant (Retisert). 2010 , 18, 305-13		16
614	Pharmacotherapy of uveitis. 2010 , 11, 1135-46		40
613	Systemic monoclonal antibody therapy (daclizumab) in the treatment of cicatrizing conjunctivitis in stevens-johnson syndrome, refractory to conventional therapy. 2010 , 35, 1057-62		4
612	TNF inhibitors for uveitis: balancing efficacy and safety. 2010 , 18, 421-3		15
611	Biologic therapy for uveitis. 2010 , 5, 225-239		1
610	Clinical experience with adalimumab in the treatment of ocular Behçet disease. 2010 , 18, 226-32		80
609	Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. <i>American Journal of Ophthalmology</i> , 2011 , 151, 630-6	4-9	34
608	Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. <i>American Journal of Ophthalmology</i> , 2011 , 152, 441-448.e2	4-9	51
607	Behçet disease: visual prognosis and factors influencing the development of visual loss. <i>American Journal of Ophthalmology</i> , 2011 , 152, 1059-66	4-9	71
606	Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. 2011 , 56, 474-510		49
605	A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. 2011 , 118, 184-90		70
604	Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. 2011 , 118, 1916-26		222

603	Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy. 2011 , 52, 6919-24	15
602	Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. 2012 , 6, 5-12	31
601	Psoriatic Eye Manifestations. 2011 , 17a, 169-179	7
600	Stem cells for ocular tissue engineering and regeneration. 2011 , 11, 1606-20	8
599	Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. 2011 , 132, 492-502	62
598	Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. 2011 , 40, 314-23	61
597	Understanding uveitis: the impact of research on visual outcomes. 2011 , 30, 452-70	196
596	Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. 2011 , 249, 1235-43	30
595	[Intravitreal implants: drug carriers and carriers of hope?]. 2011 , 108, 222-9	5
594	[Diagnosis and treatment of scleritis associated to inflammatory systemic diseases]. 2011 , 228, 419-24	0
593	Clinical review: Update on treatment of inflammatory macular edema. 2011 , 19, 75-83	34
592	Vascular endothelial growth factor inhibition in uveitis: a systematic review. 2011 , 95, 162-5	40
591	Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms. 2011 , 187, 3338-46	43
590	Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema. 2011 , 19, 353-7	16
589	Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. 2011 , 19, 286-92	34
588	Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial--lessons for comparative effectiveness trials. 2011 , 8, 736-43	10
587	Idiopathic orbital inflammatory disease. 2012 , 5, 124-5	12
586	Systemic treatment of vitreous inflammation. 2012 , 2012, 936721	1

585	The impact of macular edema on visual function in intermediate, posterior, and panuveitis. 2012 , 20, 171-81	47
584	Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. 2012 , 26, 17-28	46
583	High-dose intravenous corticosteroids for ocular inflammatory diseases. 2012 , 20, 91-9	20
582	Distinctive clinical features of idiopathic versus infectious serpiginous choroidopathy. 2012 , 20, 448-52	2
581	Management of ocular mucous membrane pemphigoid. 2012 , 7, 271-279	
580	Intravitreal corticosteroid therapy: putting the problem of glaucoma in perspective. 2012 , 130, 380-2	3
579	Imaging in the diagnosis and management of multifocal choroiditis and punctate inner choroidopathy. 2012 , 52, 243-56	15
578	Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). 2012 , 32, 537-42	27
577	Fundus autofluorescence in serpiginouslike choroiditis. 2012 , 32, 814-25	61
576	Bilateral herpes simplex keratitis presenting as peripheral ulcerative keratitis. 2012 , 31, 570-1	11
575	Susceptibility genes and pharmacogenetics in ocular inflammatory disorders. 2012 , 20, 315-23	5
574	Everolimus improves experimental autoimmune uveoretinitis. 2012 , 105, 43-52	22
573	Therapy for spondyloarthritis: the role of extra-articular manifestations (eye, skin). 2012 , 38, 583-600	5
572	Tubercular serpiginous-like choroiditis presenting as multifocal serpiginoid choroiditis. 2012 , 119, 2334-42	121
571	Mycophenolate mofetil in the treatment of chronic non-infectious, non-necrotizing scleritis. 2012 , 20, 113-8	10
570	Infliximab and adalimumab for uveitis. 2012 , 20, 18-26	45
569	Drug-induced inflammation in patients on TNF α inhibitors. 2012 , 20, 2-5	16
568	A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. 2012 , 119, 1223-30	21

567	Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. 2012 , 119, 1569-74	13
566	New treatment options for noninfectious uveitis. 2012 , 51, 134-61	30
565	Controlled drug delivery from composites of nanostructured porous silicon and poly(L-lactide). 2012 , 7, 995-1016	59
564	Maturation profiles of peripheral blood dendritic cells in patients with endogenous uveitis. 2012 , 142, 14-9	11
563	Corticosteroid-sparing therapy: practice patterns among uveitis specialists. 2012 , 2, 21-8	33
562	Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis. 2012 , 2, 177-82	7
561	Corticosteroid intravitreal implants. 2012 , 51, 122-33	19
560	Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea. 2012 , 32, 3903-8	2
559	Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. 2012 , 7, e29742	35
558	Update on peripheral ulcerative keratitis. 2012 , 6, 747-54	60
557	Clinical outcomes of cyclosporine treatment for noninfectious uveitis. 2012 , 26, 21-5	12
556	Surveying uveitis specialists-a call for consensus. 2012 , 2, 61-3	2
555	Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. 2012 , 90, 91-5	28
554	Light on the horizon: biologicals in Behçet uveitis. 2013 , 91, 297-306	14
553	Overview and recent developments in the medical management of paediatric uveitis. 2013 , 14, 1787-95	7
552	Ocular vasculitis. 2013 , 15, 355	2
551	Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. 2013 , 3, 32	69
550	Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis. 2013 , 58, 203-32	138

549	Treatment of chronic noninfectious uveitis in children--the trend toward tumor necrosis factor-alpha inhibition. 2013 , 17, 451-3	2
548	Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. 2013 , 52, 825-31	83
547	Treatment of refractory uveitic macular edema with dexamethasone intravitreal implants in a pediatric patient with bilateral granulomatous idiopathic panuveitis: a case report. 2013 , 3, 61	7
546	Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. 2013 , 120, 1201-9	23
545	Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells. 2013 , 97, 1074-8	17
544	Sympathetic Ophthalmia. 2013 , 1318-1325	2
543	Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. 2013 , 97, 481-6	90
542	Autoimmune Retinopathies. 2013 , 1381-1389	1
541	Retinal vasculitis in rheumatic diseases: an unseen burden. 2013 , 32, 7-13	45
540	Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. 2013 , 120, 186-92	123
539	Vogt-Koyanagi-Harada disease: a forgotten entity in the Canadian uveitis landscape?. 2013 , 48, 133-4	
538	Rheumatic inflammatory eye diseases of childhood. 2013 , 39, 801-32	16
537	Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. 2013 , 120, 1571-9	79
536	Scleritis: Immunopathogenesis and molecular basis for therapy. 2013 , 35, 44-62	53
535	Update in the management of extraintestinal manifestations of inflammatory bowel disease. 2013 , 15, 314	15
534	Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases. 2013 , 9, 875-82	7
533	Role of the retinal vascular endothelial cell in ocular disease. 2013 , 32, 102-80	101
532	Pharmacotherapy of scleritis: current paradigms and future directions. 2013 , 14, 411-24	41

531	Sterile Keratitis. 2013 , 3, 31-44	
530	[Sterile keratitis]. 2013 , 230, e1-14; quiz e15-6	
529	Systemic treatments for noninfectious vitreous inflammation. 2013 , 2013, 515312	8
528	Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome. 2013 , 21, 47-52	12
527	Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease. 2013 , 97, 1118-22	16
526	Medical management of uveitis - current trends. 2013 , 61, 277-83	26
525	Profile of serpiginous choroiditis in a tertiary eye care centre in eastern India. 2013 , 61, 649-52	5
524	A three-centre experience with adalimumab for the treatment of non-infectious uveitis. 2013 , 97, 134-8	58
523	Review of Intermediate Uveitis. 2013 , 2, 375-87	7
522	Response of pediatric uveitis to tumor necrosis factor- α inhibitors. 2013 , 40, 1394-403	48
521	A systematic review of biologics for the treatment of noninfectious uveitis. 2013 , 5, 91-102	16
520	The outcomes of indocyanine green angiography monitored immunotherapy in Vogt-Koyanagi-Harada disease. 2013 , 97, 130-3	12
519	Emerging drugs for the treatment of uveitis. 2013 , 18, 513-21	8
518	Corticosteroid-associated osteonecrosis: a rare, but serious, complication in uveitis. 2013 , 21, 102-7	8
517	Early treatment response of fluocinolone (retisert) implantation in patients with uveitic macular edema: an optical coherence tomography study. 2013 , 33, 873-7	9
516	Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis. 2013 , 33, 1684-93	17
515	Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. 2013 , 3, 64	21
514	Use of Methotrexate for the Treatment of Ocular Inflammation and Uveitis. 2013 , 01,	1

513	Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. 2013 , 7, 1109-44	40
512	Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. 2013 , 12, 38-45	29
511	Pharmacotherapy for uveitis: current management and emerging therapy. 2014 , 8, 1891-911	47
510	Scleral melt following Retisert intravitreal fluocinolone implant. 2014 , 8, 2373-5	5
509	Clinical profile and outcome of serpiginous choroiditis in a uveitis clinic in India. 2014 , 22, 24	1
508	[Intermediate uveitis: guidelines of the German Ophthalmological Society and the Professional Association of German Ophthalmologists]. 2014 , 111, 1033-40	5
507	Does cyclophosphamide still have a role in the treatment of severe inflammatory eye disease?. 2014 , 22, 306-10	7
506	Chitosan oligosaccharides attenuate ocular inflammation in rats with experimental autoimmune anterior uveitis. 2014 , 2014, 827847	20
505	Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors. 2014 , 22, 469-77	26
504	Corneal Biomechanical Characteristics in Patients with Behçet Disease. 2016 , 31, 439-45	5
503	Treatment with immunosuppressive therapy in patients with pars planitis: experience of a reference centre in Mexico. 2014 , 98, 1503-7	8
502	Retrospective analysis of the natural history and management of serpiginous choroiditis in Australia and New Zealand. 2014 , 42, 656-64	3
501	Ocular Health, Vision, and a Healthy Diet. 2014 , 267-277	1
500	[Therapy of intermediate uveitis]. 2014 , 111, 1219-32; quiz 1233-4	3
499	Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation. 2014 , 55, 2788-94	19
498	Optical coherence tomography and histopathology of macular uveitis. 2014 , 91, 1335-42	5
497	Cystoid Macular Edema. 2014 , 219-230	
496	Quality of life in non-infectious uveitis patients on immunosuppressive therapy. 2014 , 21, 225-31	15

495	Validation of a Brief Questionnaire Measuring Positive Mindset in Patients With Uveitis. 2014 , 3, 1-10	4
494	Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. 2014 , 8, 67-81	68
493	Anti-TNF- α agents for refractory cystoid macular edema associated with noninfectious uveitis. 2014 , 252, 633-40	34
492	Biologic agents in experimental autoimmune uveitis. 2014 , 34, 145-56	5
491	Noninfectious immune-mediated uveitis and ocular inflammation. 2014 , 14, 409	36
490	Ocular inflammatory diseases associated with rheumatoid arthritis. 2014 , 10, 108-16	72
489	Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders. 2014 ,	2
488	Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. 2014 , 121, 785-96.e3	308
487	INTERNATIONAL SOCIETY OF PHARMACOVIGILANCE. 2014 , 37, 831-891	1
486	Systemic use of non-biologic corticosteroids in orofacial diseases. 2014 , 20, 127-35	5
485	Side-effects of anti-inflammatory therapy in uveitis. 2014 , 29, 456-67	20
484	A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. 2014 , 15, 2141-54	19
483	Recurrence of uveitis after discontinuation of infliximab. 2014 , 22, 96-101	23
482	Success with single-agent immunosuppression for multifocal choroidopathies. <i>American Journal of Ophthalmology</i> , 2014 , 158, 1310-7	4.9 20
481	[Uveitis in multiple sclerosis : Overview and perspectives]. 2014 , 111, 733-9	5
480	Review of Systemic Immunosuppression for Autoimmune Uveitis. 2014 , 3, 17-36	12
479	New pharmacotherapy options for noninfectious posterior uveitis. 2014 , 14, 1783-99	6
478	Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis. 2014 , 121, 1119-24	19

477	Long-term results of fluocinolone acetonide intravitreal implant in Behçt intractable posterior uveitis. 2014 , 49, 273-8	8
476	A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. 2014 , 121, 1863-70	73
475	Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. 2014 , 121, 1855-62	36
474	Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. 2014 , 34, 1666-74	20
473	Ophthalmic Procedures for Treatment of Advanced Ocular Surface Diseases. 2015 , 92, 939-47	2
472	Current management approaches for uveitic glaucoma. 2015 , 55, 141-60	10
471	Recalcitrant psoriatic uveitis and anti-tumor necrosis factor- α monoclonal antibodies: experience from a psoriasis referral center. 2015 , 54, 1105-8	4
470	Vogt-Koyanagi-Harada disease. 2015 , 26, 506-11	29
469	Clinical trials in noninfectious uveitis. 2015 , 55, 79-110	13
468	Mycophenolate mofetil therapy in scleritis: Analysis of seven cases in tertiary eye hospital in India. 2015 , 5, 33-37	
467	A Clinical Picture of the Visual Outcome in Adamantiades-Behçt's Disease. 2015 , 2015, 120519	4
466	Inflammation and keratoconus. 2015 , 92, e35-41	65
465	Posterior Uveitis. 2016 , 55, 163-6	5
464	Immunomodulatory Therapy in Uveitis. 2016 , 55, 265-75	5
463	Factors affecting therapeutic decisions in intermediate and posterior uveitis. <i>American Journal of Ophthalmology</i> , 2015 , 159, 213-20.e3	4.9 12
462	Immunosuppressive therapy and cancer risk in ocular inflammation patients: fresh evidence and more questions. 2015 , 122, 219-21	4
461	Regulatory T cell levels and cytokine production in active non-infectious uveitis: in-vitro effects of pharmacological treatment. 2015 , 179, 529-38	15
460	Detection of Mycobacterium tuberculosis genome in vitreous fluid of eyes with multifocal serpiginoid choroiditis. 2015 , 122, 840-50	31

459	Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. 2015 , 122, 265-73		16
458	Experience of scleritis and episcleritis at a tertiary center in Southern Taiwan. 2015 , 5, 19-22		6
457	Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial. <i>American Journal of Ophthalmology</i> , 2015 , 159, 601-6	4-9	14
456	Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. 2015 , 93, e475-80		28
455	Uveitis in adults: What do rheumatologists need to know?. 2015 , 82, 308-14		16
454	Uv�tes de l'adulte : que doit savoir le rhumatologue ?. 2015 , 82, 298-305		
453	Equine recurrent uveitis: Human and equine perspectives. 2015 , 206, 22-9		26
452	Therapeutic options for the treatment of non-infectious uveitis. 2015 , 10, 359-373		2
451	Uveitis. 2015 , 42, 305-23		23
450	Approved for use in uveitis drug approval for an orphan disease. 2015 , 3, 799-807		1
449	Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors. <i>American Journal of Ophthalmology</i> , 2015 , 160, 193-200.e1	4-9	23
448	The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. 2015 , 17, 283-301		14
447	Current medical and surgical therapeutic approaches to cystoid macular edema in uveitis. 2015 , 10, 49-58		1
446	Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals. 2015 , 59, 157-63		23
445	Magnetic resonance imaging of uveitis. 2015 , 57, 825-32		8
444	Outcome of Multiple Implants and Dissociation of Fluocinolone Acetonide Intraocular Implant (Retisert) in a Series of 187 Consecutive Implants. 2015 , 23, 425-9		6
443	Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study. 2015 , 122, 1976-86		39
442	Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. <i>American Journal of Ophthalmology</i> , 2015 , 160, 1133-1141.e5	4-9	25

441	Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results. 2015 , 122, 2351-9		54
440	[Guideline of the Professional Association of German Ophthalmologists eV and the German Ophthalmology Society: Guideline No. 24a: Uveitis intermedia (July 2014)]. 2015 , 232, 79-84		0
439	Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. 2015 , 122, 1967-75		57
438	Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis. 2015 , 253, 1777-82		26
437	Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention. 2015 , 5, 156-163		13
436	Ocular Sarcoidosis. 2015 , 36, 669-83		97
435	Uveitis in Behçet disease in a tertiary center over 25 years: the KKESH Uveitis Survey Study Group. <i>American Journal of Ophthalmology</i> , 2015 , 159, 177-84.e1-2	4.9	29
434	[Biologics in uveitis]. 2015 , 36, 107-16		6
433	Mycophenolate Mofetil for Chronic Uveitis in Koreans. 2016 , 57, 283		
432	Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis. 2016 , 79, 369-372		2
431	Engineered nanomaterials for biomedicine: Advancements and hazards. 2016 , 307-328		2
430	Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis. 2016 , 25, 363-71		1
429	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. 2016 , 68, 1522-30		96
428	Dexamethasone intravitreal implant in serpiginous choroiditis. 2017 , 101, 327-332		8
427	[Treatment of posterior noninfectious uveitis : Current situation and future developments]. 2016 , 113, 380-90		1
426	Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis. 2018 , 26, 642-650		5
425	Differenzialdiagnose der anterioren intraokularen Entzündung. 2016 , 30, 249-262		
424	A TLR9 agonist promotes IL-22-dependent pancreatic islet allograft survival in type 1 diabetic mice. 2016 , 7, 13896		12

423	Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy. 2016 , 91, 138-141	
422	Neopterin Release and Tryptophan Degradation in Patients with Uveitis. 2016 , 41, 1513-1517	8
421	Diagnosis and management of non-infectious immune-mediated scleritis: current status and future prospects. 2016 , 12, 827-37	11
420	Vogt-Koyanagi-Harada syndrome: Perspectives for immunogenetics, multimodal imaging, and therapeutic options. 2016 , 15, 809-19	40
419	Manual of Retinal Diseases. 2016 ,	1
418	Multifocal Choroiditis and Panuveitis. 2016 , 451-455	
417	Birdshot Chorioretinopathy. 2016 , 475-479	
416	[Differential diagnosis of anterior uveitis]. 2016 , 113, 879-892	5
415	Adalimumab in Patients with Active Noninfectious Uveitis. 2016 , 375, 932-43	310
414	Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masked Uveitis TReAtment (SAKURA). 2016 , 123, 2413-2423	56
413	Obituary. <i>American Journal of Ophthalmology</i> , 2016 , 169, 300-302	4-9 0
412	Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. 2016 , 388, 1183-92	249
411	[Diagnosis and treatment of episcleritis and scleritis]. 2016 , 113, 797-810	11
410	Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. 2016 , 123, 1940-8	31
409	Pharmacologic Treatment of Noninfectious Uveitis. 2017 , 242, 231-268	5
408	A national survey of Canadian ophthalmologists to determine awareness of published guidelines for the management of uveitis. 2016 , 6, 38	2
407	Posterior scleritis. 2016 , 11, 475-484	4
406	HLA-B27 Anterior Uveitis: Immunology and Immunopathology. 2016 , 24, 450-9	29

405	Immunosuppressive Drug Discontinuation in Noninfectious Uveitis From Real-Life Clinical Practice: A Survival Analysis. <i>American Journal of Ophthalmology</i> , 2016 , 169, 1-8	4.9	8
404	Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies. <i>American Journal of Ophthalmology</i> , 2016 , 168, 279-286	4.9	15
403	Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy. 2016 , 91, 138-41		3
402	Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. 2016 , 11, 29		102
401	Visual response and anatomical changes on sequential spectral-domain optical coherence tomography in birdshot chorioretinopathy treated with local corticosteroid therapy. 2016 , 2, 9		5
400	Uveitis: An Update. 2016 ,		1
399	Non-Infectious Uveitis: Optimising the Therapeutic Response. 2016 , 76, 27-39		13
398	Multisystem diseases affecting the skin and eye. 2016 , 34, 214-41		5
397	Autoimmune Bullous Diseases. 2016 ,		1
396	Uveitic Macular Edema: Treatment Update. 2016 , 4, 30-37		18
395	Sirolimus for the treatment of noninfectious uveitis. 2016 , 17, 127-35		11
394	Rituximab in the Treatment of Refractory Noninfectious Scleritis. <i>American Journal of Ophthalmology</i> , 2016 , 164, 22-8	4.9	34
393	Review of the latest systemic treatments for chronic non-infectious uveitis. 2016 , 11, 111-133		2
392	Behçet Disease. 2016 , 17-31		3
391	Corticosteroid in Uveitis. 2016 , 43-48		
390	Immunosuppressives in Uveitis and Ocular Inflammation. 2016 , 75-91		
389	Mycophenolate Mofetil Therapy in Refractory Inflammatory Eye Disease. 2016 , 32, 55-61		5
388	Pattern of Pediatric Uveitis Seen at a Tertiary Referral Center from India. 2016 , 24, 402-9		36

387	Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center. 2016 , 24, 521-9	19
386	Flurbiprofen: A Nonselective Cyclooxygenase (COX) Inhibitor for Treatment of Noninfectious, Non-necrotizing Anterior Scleritis. 2016 , 24, 35-42	16
385	The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. 2016 , 61, 1-17	95
384	Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review. 2017 , 20, 225-230	25
383	Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. 2017 , 16, 213-222	18
382	Serpiginous choroidopathy. 2017 , 12, 123-132	
381	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. 2017 , 16, 237-243	20
380	Synthesis of fullerene (C-monoadduct)-based water-compatible imprinted micelles for electrochemical determination of chlorambucil. 2017 , 94, 115-123	30
379	Scleritis. 2017 ,	1
378	Peripheral Ulcerative Keratitis. 2017 ,	1
377	Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation. 2017 , 61, 169-178	3
376	Outcomes of cataract surgery with/without vitrectomy in patients with pars planitis and immunosuppressive therapy. 2017 , 255, 1213-1219	0
375	Management of Uveitis and Scleritis in Necrobiotic Xanthogranuloma. 2017 , 33, 325-333	5
374	Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. 2017 , 135, 511-518	42
373	Improving More Than Just Vision in Noninfectious Uveitis. 2017 , 135, 518-519	
372	Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis. <i>American Journal of Ophthalmology</i> , 2017 , 179, 10-17	4.9 16
371	Sympathetic Ophthalmia. 2017 , 25, 149-151	36
370	Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis. <i>American Journal of Ophthalmology</i> , 2017 , 179, 171-178	4.9 7

369	Association Between Long-Lasting Intravitreal Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. 2017 , 317, 1993-2005		63
368	Comparative efficacy of steroid-sparing therapies for non-infectious uveitis. 2017 , 12, 313-319		10
367	Acute administration of cyclosporine A does not impair attention or memory performance in healthy men. 2017 , 28, 255-261		2
366	Birdshot retinochoroidopathy: pathophysiology, diagnosis and treatment. 2017 , 5, 321-329		
365	Management of Scleritis with Immunosuppressive Drugs and Biologic Agents. 2017 , 99-120		
364	Cyclosporine: A Historical Perspective on Its Role in the Treatment of Noninfectious Uveitis. 2017 , 33, 247-262		5
363	A Bayesian Analysis of a Randomized Clinical Trial Comparing Antimetabolite Therapies for Non-Infectious Uveitis. 2017 , 24, 63-70		9
362	Successful long-term treatment of paraneoplastic optic neuropathy with mycophenolate mofetil, prednisone, and plasmapheresis. 2017 , 8, 31-34		3
361	Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices. 2017 , 32, 48-61		9
360	Clinical Implications of Direct Immunofluorescence Findings in Patients With Ocular Mucous Membrane Pemphigoid. <i>American Journal of Ophthalmology</i> , 2017 , 183, 48-55	4.9	21
359	Posterior drug delivery via periocular route: challenges and opportunities. 2017 , 8, 685-699		22
358	OZURDEX [®] (Dexamethasone Intravitreal Implant) 0.7 mg for Use in Noninfectious Posterior Segment Uveitis: A Case-Based Discussion. 2017 , 37, 1-16		12
357	Small molecules as therapy for uveitis: a selected perspective of new and developing agents. 2017 , 18, 1311-1323		8
356	Tubulointerstitial nephritis and uveitis. 2017 , 28, 629-635		29
355	[DOG and BVA guideline no. 24b : Noninfectious uveitis posterior]. 2017 , 114, 1122-1134		0
354	Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. 2017 , 124, 1799-1807		22
353	Long-term immunosuppressive therapy for inflammatory eye disease [the link between systemic treatment, cardiovascular risk and disease?]. 2017 , 12, 321-330		0
352	Systemic Treatment for Noninfectious Intraocular Inflammation. 2017 , 5, 98-105		

351	Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles. 2017 , 110, 58-69	106
350	Imaging of Exudative Age-Related Macular Degeneration: Toward a Shift in the Diagnostic Paradigm?. 2017 , 38 Suppl 1, 1-12	6
349	Clinical spectrum and management options in Vogt-Koyanagi-Harada disease. 2017 , 11, 1399-1406	14
348	Evaluation of the Glucocorticoid Receptor as a Biomarker of Treatment Response in Vogt-Koyanagi-Harada Disease. 2017 , 58, 974-980	12
347	High Levels of Serum Ubiquitin and Proteasome in a Case of HLA-B27 Uveitis. 2017 , 18,	2
346	Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis. 2017 , 8, 1121	31
345	Additive Effect of Oral Steroid with Topical Nonsteroidal Anti-inflammatory Drug for Preventing Cystoid Macular Edema after Cataract Surgery in Patients with Epiretinal Membrane. 2017 , 31, 394-401	4
344	A retrospective cohort study of patients treated with anti-tuberculous therapy for presumed ocular tuberculosis. 2017 , 7, 23	9
343	An update on isolated retinal vasculitis. 2017 , 59,	
342	Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone. 2017 , 11, 1949-1956	6
341	The Eye and Rheumatic Diseases. 2017 , 645-653	2
340	Ophthalmic manifestations in patients with inflammatory bowel disease: A review. 2017 , 23, 5836-5848	52
339	The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. 2018 , 256, 801-808	18
338	Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. 2018 , 102, 1672-1678	18
337	Ocular Involvement in Sjögren's Syndrome: Advances in Therapy. 2018 , 4, 99-109	4
336	Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. 2018 , 125, 1075-1087	81
335	Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU). 2018 , 168, 49-56	10
334	Glucocorticoid receptor GR β regulates glucocorticoid-induced ocular hypertension in mice. 2018 , 8, 862	13

333	Swept-Source OCT Angiography of Serpiginous Choroiditis. 2018 , 2, 712-719		29
332	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for Uveitis (FOCUS) Initiative. 2018 , 125, 757-773		97
331	Traitements systémiques des uvéites. 2018 , 39, A37-A44		
330	[Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel]. 2018 , 39, 687-698		3
329	[DOG and BVA Guideline No. 24b - Noninfectious uveitis posterior]. 2018 , 235, 94-107		0
328	Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs. <i>American Journal of Ophthalmology</i> , 2018 , 193, 197-229	4.9	14
327	Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease. 2018 , 26, 485-489		24
326	Medical Malpractice in Uveitis: A Review of Clinical Entities and Outcomes. 2018 , 26, 242-248		11
325	Screening for Depression and Anxiety in Patients with Active Uveitis. 2018 , 26, 1078-1093		17
324	Immunosuppression for the Uveitides. 2018 , 125, 193-202		62
323	Efficacy of infliximab in refractory posterior uveitis in Behcet's disease patients. 2018 , 40, 93-97		2
322	Can Appropriate Systemic Treatment Help Protect the Cornea in Patients With Rheumatoid Arthritis? A Multidisciplinary Approach to Autoimmune Ocular Involvement. 2018 , 37, 235-241		6
321	Are Adverse Events Induced by the Acute Administration of Calcineurin Inhibitor Cyclosporine A Behaviorally Conditioned in Healthy Male Volunteers?. 2018 , 40, 1868-1877		3
320	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. 2018 , 2018, 9460187		9
319	High-Dimensional Profiling Reveals Heterogeneity of the Th17 Subset and Its Association With Systemic Immunomodulatory Treatment in Non-infectious Uveitis. 2018 , 9, 2519		8
318	Ocular cicatricial pemphigoid. 2018 , 29, 543-551		13
317	Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment. 2018 , 2018, 5072582		22
316	The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative. 2018 , 41, 759-766		8

315	Novel therapies in the treatment of noninfectious uveitis. 2018 , 13, 139-147	1
314	[Systemic Corticosteroids in Non-infectious Uveitis]. 2018 , 235, 592-596	0
313	Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis. 2018 , 125, 1977-1983	40
312	Cataract Surgery in Patients with Uveitis: Preoperative and Surgical Considerations. 2018 ,	0
311	Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies. 2018 , 125, 1984-1993	18
310	Management of chronic ocular sarcoidosis: challenges and solutions. 2018 , 12, 519-532	19
309	Re: Dick et al.: Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for Uveitis (FOCUS) Initiative (Ophthalmology. 2018;125:757-773). 2018 , 125, e53-e54	6
308	The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study. 2018 , 256, 1985-1992	15
307	mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis: a systematic review protocol. 2018 , 7, 83	1
306	[Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis]. 2018 , 235, 562-567	
305	11 Cystoid Macular Edema. 2018 ,	
304	25 Noninfectious Chorioretinal Inflammatory Conditions. 2018 ,	
303	Cyclosporine A-Loaded Nanocarriers for Topical Treatment of Murine Experimental Autoimmune Uveoretinitis. 2018 , 15, 2539-2547	2
302	Clinical features of paediatric uveitis at a tertiary referral centre in Sã Paulo, SP, Brazil. 2018 ,	12
301	Clinical Features of Scleritis Across the Asia-Pacific Region. 2019 , 27, 920-926	13
300	Surgical Intervention in Inciting Eyes of Patients with Sympathetic Ophthalmia: A Case Series and Review of Literature. 2019 , 27, 1154-1159	4
299	Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials. 2019 , 27, 40-50	12
298	Recent progress in the treatment of uveitic macular edema. 2019 , 14, 227-236	2

297	Conjunctivitis Preferred Practice Pattern . 2019 , 126, P94-P169	28
296	Intravitreal dexamethasone implants for non-infectious uveitis. 2019 , 47, 1156-1163	1
295	Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. 2019 , 9, 3	14
294	Glucocorticoid Receptor- and MKP-1 as Candidate Biomarkers for Treatment Response and Disease Activity in Vogt-Koyanagi-Harada Disease. <i>American Journal of Ophthalmology</i> , 2019 , 207, 319-325	4
293	Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases. <i>American Journal of Ophthalmology</i> , 2019 , 208, 68-75	4-9 14
292	The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014. 2019 , 38, 3211-3215	7
291	Adrenocorticotrophic hormone gel for patients with non-infectious uveitis. 2019 , 15, 100502	5
290	Resolution of uveitis. 2019 , 41, 727-736	11
289	Biologic therapy for uveitis: a new beginning. 2019 , 49, 1349-1351	5
288	When to Consider Bisphosphonates in Patients on Steroids for Chronic Ocular Inflammatory Conditions. 2019 , 35, 379-380	1
287	Psoriasis and uveitis: links and risks. 2019 , 9, 91-96	17
286	Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. 2019 , 322, 936-945	42
285	Emerging drugs for the treatment of noninfectious uveitis. 2019 , 24, 173-190	5
284	Uveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand. 2019 , 8, 11	4
283	Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. 2019 , 13, 1761-1777	14
282	Biological Therapies that Target Inflammatory Cytokines to Treat Uveitis. 2019 ,	3
281	Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. 2019 , 97, 460-472	30
280	Outcomes of treatment with sirolimus for non-infectious uveitis: a meta-analysis and systematic review. 2019 , 13, 649-669	6

279	Tissue-specific production of MicroRNA-155 inhibits melanocortin 5 receptor-dependent suppressor macrophages to promote experimental autoimmune uveitis. 2019 , 49, 2074-2082	6
278	Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center. 2019 , 38, 2917-2923	
277	New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. 2019 , 49, 438-445	27
276	Glucocorticoid Receptor Transactivation Is Required for Glucocorticoid-Induced Ocular Hypertension and Glaucoma. 2019 , 60, 1967-1978	17
275	Posterior Uveitis. 2019 ,	
274	Expert opinion on the use of biological therapy in non-infectious uveitis. 2019 , 19, 477-490	29
273	Peripheral ulcerative keratitis with corneal melt as the primary presentation in a case of human immunodeficiency virus. 2019 , 12,	0
272	Update in treatment of uveitic macular edema. 2019 , 13, 667-680	22
271	Noninfectious Uveitis: Systemic and Local Corticosteroids. 2019 , 159-174	
270	New therapies in development for the management of non-infectious uveitis: A review. 2019 , 47, 396-417	26
269	Adalimumab for non-infectious uveitis: is it cost-effective?. 2019 , 103, 1633-1638	3
268	Dexamethasone implant for non-infectious uveitis: is it cost-effective?. 2019 , 103, 1639-1644	2
267	Inflammatory eye and rheumatic disease. 2019 , 22, 2091-2095	2
266	Current and Emerging Pharmaceutical Therapies for Noninfectious Uveitis. 2019 , 59, 111-126	1
265	Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: A multicenter study. 2019 , 98, e14668	8
264	Safety of systemic therapy for noninfectious uveitis. 2019 , 18, 1219-1235	4
263	The use of biologics for uveitis associated with spondyloarthritis. 2019 , 31, 349-354	12
262	Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. 2019 , 26, 27-46	4

261	Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. 2019 , 296, 68-80	29
260	Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan. 2019 , 21, 2	20
259	A reduced graphene oxide ceramic electrode modified with one MoNomer doubly imprinted acryloylated tetraamine cobalt phthalocyanine polymer for the simultaneous analysis of anticancerous drugs. 2019 , 281, 139-149	10
258	Use of Immunomodulatory Drugs at a Uveitis Clinic. 2019 , 15, 271-276	
257	Use of Immunomodulatory Drugs at a Uveitis Clinic. 2019 , 15, 271-276	0
256	Anti-Inflammatory Effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor-B Inhibitor, on Endotoxin-Induced Uveitis in Rats In vivo and In vitro. 2020 , 28, 240-248	7
255	Indicators of Post-Operative Intraocular Pressure Elevation after Na ⁺ Fluocinolone Acetonide Surgical Implantation. 2020 , 28, 828-832	1
254	Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial. 2020 , 34, 491-498	1
253	Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioUea) Study Group. 2020 , 127, 814-825	11
252	Sirolimus loaded polyol modified liposomes for the treatment of Posterior Segment Eye Diseases. 2020 , 136, 109518	9
251	Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review. 2020 , 50, 1299-1306	7
250	Curcumin-loaded proniosomal gel as a biofriendly alternative for treatment of ocular inflammation: In-vitro and in-vivo assessment. 2020 , 589, 119835	14
249	Chitosan Oligosaccharides Suppress Nuclear Factor-Kappa B Activation and Ameliorate Experimental Autoimmune Uveoretinitis in Mice. 2020 , 21,	1
248	Sympathetic Ophthalmia. 2020 , 1-15	1
247	Ocular Sarcoidosis. 2020 , 41, 673-688	7
246	[The learned placebo response in the immune system]. 2020 , 91, 667-674	1
245	Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset. <i>American Journal of Ophthalmology</i> , 2020 , 220, 37-44	4-9 4
244	Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy. 2020 , 1-5	2

243	Pseudopemphigoid: Sarcoidosis presenting as cicatricial conjunctivitis with symblepharon. 2020 , 1120672120969046	
242	Effectiveness of the Dexamethasone Implant in Lieu of Oral Corticosteroids in Intermediate and Posterior Uveitis Requiring Immunosuppression. 2020 , 1-9	0
241	Definition of Uveitis Refractory to Treatment: A Systematic Review in the Absence of a Consensus. 2020 , 1-6	4
240	Anti-TNF- α therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients. 2020 , 1-8	10
239	Systemic anti-inflammatory therapy aided by double-headed nanoparticles in a canine model of acute intraocular inflammation. 2020 , 6, eabb7878	6
238	Efficacy and Safety of Corticosteroid Implants in Non-infectious Uveitis: A Systematic Review with Network Meta-analysis. 2020 , 1-8	2
237	The Impact of Adult Uveitis on Quality of Life: An Exploratory Study. 2021 , 28, 444-452	2
236	The efficacy of adalimumab in treating patients with central multifocal choroiditis. 2020 , 20, 100921	3
235	The efficacy of corticosteroid-sparing immunomodulatory therapy in treating patients with central multifocal choroiditis. 2020 , 98, 816-821	6
234	Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. 2020 , 127, 1405-1415	12
233	Kallistatin Attenuates Experimental Autoimmune Uveitis by Inhibiting Activation of T Cells. 2020 , 11, 975	2
232	Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation. 2020 , 117, 6067-6074	10
231	Risk of Cataract Development among Children with Juvenile Idiopathic Arthritis-Related Uveitis Treated with Topical Corticosteroids. 2020 , 127, S21-S26	6
230	Serum KL-6 elevation in a uveitis patient with Behçet's disease treated with adalimumab. 2020 , 18, 100660	1
229	Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy. 2020 , 9,	4
228	NONINFECTIOUS POSTERIOR UVEITIS: BRINGING EMERGING TREATMENTS TO THE FOREFRONT. 2020 , 40 Suppl 3, S1-S12	
227	Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy. <i>American Journal of Ophthalmology</i> , 2020 , 219, 303-316	4.9 0
226	The effectiveness and safety of Chinese medicines for the treatment of uveitis: A protocol for systematic review and meta-analysis. 2020 , 99, e20766	0

225	Vogt-Koyanagi-Harada disease presenting secondary to a post-infectious autoimmune response. 2020 , 19, 100793	4
224	Recent advances in the management of non-infectious posterior uveitis. 2020 , 40, 3187-3207	1
223	Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. 2020 , 258, 1023-1030	9
222	Two cases of perforated corneal ulcers complicating rheumatoid arthritis treated successfully by biological therapy. 2020 , 4, 6	5
221	[Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis]. 2020 , 43, 341-361	1
220	Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer. 2020 , 18, 100691	3
219	Systemic Immunosuppression Is Highly Effective in the Long-term Control of Inflammatory non-infectious Uveitic Choroidal Neovascularization: A Comparative Study. 2020 , 1-5	11
218	Impact of systemic treatments on the course of HLA-B27-associated uveitis: A retrospective study of 101 patients. 2020 , 15, e0230560	7
217	Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. 2021 , 80, 100866	23
216	Use of Anti-Tumour Necrosis Factor-Alpha Agents in the Management of HLA-B-27-Associated Uveitis: The First Case Series from India. 2021 , 29, 232-236	0
215	Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors. <i>American Journal of Ophthalmology</i> , 2021 , 223, 377-395	4-9 9
214	[Guidelines nr. 24a intermediate uveitis]. 2021 , 118, 16-30	0
213	Disease Relapse After Drug-Free Remission in Ocular Mucous Membrane Pemphigoid. <i>American Journal of Ophthalmology</i> , 2021 , 223, 21-27	4-9 1
212	Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. 2021 , 20, 102735	27
211	Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. 2021 , 128, 719-728	8
210	Serpiginous Choroiditis Presenting in Association With <i>Clostridium difficile</i> Infection and Ulcerative Colitis. 2021 , 5, 177-181	
209	Structured teaching programme enhances the knowledge of mothers to take care of children with leukaemia. 2021 , 29, 55-60	
208	A Study to Analyse the Presentation of Autoimmune and Idiopathic Serpiginous Choroiditis in Indian Population. 2021 , 8, 224-229	

207	Cyclosporine A Promotes Bone Remodeling in LPS-Related Inflammation via Inhibiting ROS/ERK Signaling: Studies and. 2021 , 2021, 8836599	1
206	Pediatric uveitis: a retrospective analysis at a tertiary eye care hospital in South India. 2021 , 13, 25158414211027707	
205	Uveitis for the non-ophthalmologist. 2021 , 372, m4979	12
204	Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities. 2021 , 330, 438-460	5
203	Treatment Exit Options for Non-infectious Uveitis (TOFU): Study Protocol for a Prospective Clinical Registry. 2021 , 1-8	2
202	Neuro-ophthalmologic manifestations of multiple sclerosis other than acute optic neuritis. 2021 , 48, 102730	0
201	Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study. 2021 , 35, 3342-3349	2
200	Pediatric Behçet's Disease. 2021 , 8, 627192	9
199	Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists. 2021 , 67,	1
198	Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. 2021 , 10, 360-365	4
197	Risk of Non-infectious Uveitis with Metformin Therapy in a Large Healthcare Claims Database. 2021 , 1-7	1
196	Management of repository corticotropin injection therapy for non-infectious uveitis: a Delphi study. 2021 , 99, 669-678	0
195	A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study. 2021 , 159, 105735	13
194	Ultra-Widefield Fluorescein Angiography to Monitor Therapeutic Response to Adalimumab in Behçet's Uveitis. 2021 , 1-7	1
193	Outcomes of Repository Corticotropin Gel for Ocular Sarcoidosis. 2021 , 1-5	1
192	Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment. 2021 , 1-6	4
191	Temperature-responsive voltammetric sensor based on stimuli-sensitive semi-interpenetrating polymer network conductive microgels for reversible switch detection of nitrogen mustard analog chlorambucil (Leukeran) 2021 , 374, 137866	4
190	Understanding Immune Responses to Surgical Transplant Procedures in Stevens Johnsons Syndrome Patients. 2021 , 8, 656998	0

189	Efficacy of Tacrolimus in Uveitis, and the Usefulness of Serum Tacrolimus Levels in Predicting Disease Control. Results from a Single Large Center. 2021 , 1-5		1
188	The use of systemic mycophenolate in canine immune-mediated ophthalmic disease. 2021 , 9, e100		0
187	The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet's Retinal Vasculitis. 2021 , 12, 609148		3
186	Treatment experience in a HIV-infected patient with Vogt-Koyanagi-Harada disease- a case report. 2021 , 1-5		
185	Surgical Outcomes of Contrast Sensitivity and Visual Acuity in Uveitis-Associated Cataract. 2021 , 15, 2665-2673		
184	Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre. 2021 , 1-7		1
183	The clinical and pathogenic spectrum of surgically-induced scleral necrosis: A review. 2021 , 66, 594-611		2
182	Immunomodulatory nanosystems for treating inflammatory diseases. 2021 , 274, 120875		8
181	Vascular abnormalities in uveitis. 2021 , 66, 653-667		2
180	Blocking the inflammasome: A novel approach to treat uveitis. 2021 , 26, 2839-2857		3
179	Systemic Immunosuppression in Cornea and Ocular Surface Disorders: A Ready Reckoner for Ophthalmologists. 2021 , 1-15		0
178	Cost-Utility Analysis of Mycophenolate Mofetil versus Methotrexate for Noninfectious Uveitis. 2021 , 5, 1281-1282		
177	Risk of Cataract in Intermediate Uveitis. <i>American Journal of Ophthalmology</i> , 2021 , 229, 200-209	4.9	2
176	Novel strategies for the diagnosis and treatment of scleritis. 1-18		
175	Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. 2021 , 6, e000819		1
174	The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies. 2021 , 12, 620340		0
173	Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis. 2021 , 128, 1337-1345		3
172	Down regulation of inflammatory cytokines by the bioactive resveratrol-loaded chitoniosomes in induced ocular inflammation model. 2021 , 66, 102787		1

171	Ocular Manifestations of Systemic Vasculitides. 2021 , 1-48	
170	Gastrointestinal and Nutritional Disorders. 2021 , 1-31	
169	Diagnosis and Management of Ocular Inflammatory Disease. 2019 , 289-309	1
168	General Principles of Medical Therapy. 2017 , 35-49	1
167	Steroid Sensitivity in Uveitis. 2009 , 45-54	1
166	Crohn's Disease and Ulcerative Colitis. 2016 , 719-729	3
165	Multiple Sclerosis. 2016 , 851-861	1
164	Safety of Immunosuppressive Therapy for Eye Diseases. 2014 , 231-244	1
163	Diagnosis and Management of Scleritis. 2014 , 41-61	1
162	Anterior Uveitis: Differential Diagnosis. 2020 , 53-61	1
161	Inflammatory Bowel Disease [Crohn's Disease and Ulcerative Colitis]. 2014 ,	1
160	Rheumatic Diseases. 2006 , 1383-1408	2
159	Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY). 2020 ,	5
158	Emerging therapies in the management of macular edema: a review. 2019 , 8,	21
157	Silibinin treatment prevents endotoxin-induced uveitis in rats in vivo and in vitro. 2017 , 12, e0174971	11
156	Ocular Manifestations of Rheumatoid Arthritis: Implications of Recent Clinical Trials. 2019 , 4,	7
155	A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. 2017 , 21, 1-170	20
154	New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview. 2020 , 11, 655	10

153	An evidence-based review of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 2. Coats' disease, best disease, and uveitis with childhood neovascularization. 2013 , 50, 11-9	12
152	Specialty Practice and Cost Considerations in the Management of Uveitis Associated With Juvenile Idiopathic Arthritis. 2016 , 53, 246-51	5
151	Treatment of uveitis: beyond steroids. 2010 , 58, 1-2	8
150	Treatment Results in Serpiginous Choroiditis and Multifocal Serpiginoid Choroiditis Associated with Latent Tuberculosis. 2017 , 47, 89-93	6
149	Behçet's Uveitis: Current Diagnostic and Therapeutic Approach. 2020 , 50, 169-182	2
148	Pediatric Behçet's disease - clinical aspects and current concepts. 2019 , 1-10	8
147	Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model. 2021 , 13,	0
146	The Pattern of Uveitis in a Pediatric Population at a Tertiary Center in Thailand. 2021 , 1-9	1
145	Immunotherapy for ocular inflammatory disease. 2003 , 49-58	
144	Management of Intraocular Inflammation. 2006 , 1011-1016	
143	Vogt-Koyanagi-Harada Disease (Uveomeningitic Syndrome). 2008 , 1201-1209	1
142	Intermediate Uveitis. 2008 , 1161-1172	
141	Introduction to Uveitis. 2008 , 1113-1122	
140	Ocular Manifestations of Systemic Vasculitides. 2008 , 4831-4857	
139	A 36-year-old man with a red eye. 2008 , 14, 20-23	
138	Immunosuppression. 2008 , 1123-1136	
137	Immunomodulatory Therapy. 2008 , 149-179	
136	New developments in the management of juvenile idiopathic arthritis-related uveitis. 2008 , 3, 587-598	

- 135 Uveitis Related to HLA-B27 and Juvenile Arthritis. **2009**, 838-843
- 134 GENERAL APPROACH TO THE UVEITIS PATIENT AND TREATMENT STRATEGIES. **2009**, 783-788
- 133 TREATMENT OF POSTERIOR UVEITIS WITH A FLUOCINOLONE ACETONIDE IMPLANT. **2009**, 10, 224-226 2
- 132 Apport des modèles expérimentaux d'inflammation oculaire. **2010**, 47-75
- 131 Immunologic mechanisms of uveitis. **2010**, 618-627
- 130 Corneal Disease in Rheumatoid Arthritis. **2011**, 1117-1132 1
- 129 Idiopathic Uveitis. **2011**, 1277-1284
- 128 The eye in rheumatic disease. **2011**, 297-303.e2
- 127 Entzündliche Gefäßkrankungen. **2012**, 335-398
- 126 Diseases of the Head and Neck. **2012**, 279-319
- 125 Vogt-Koyanagi-Harada Disease. **2013**, 353-376
- 124 Okuläre Oberfläche (nicht infektiös). **2014**, 117-180
- 123 Therapie: Grundkonzepte. **2014**, 253-283
- 122 The eye in rheumatic disease. **2015**, 260-266
- 121 Methotrexate. **2016**, 355-361 1
- 120 Ocular Cicatricial Pemphigoid. **2016**, 75-97
- 119 Azathioprine. **2016**, 309-314
- 118 Romatoid Artritite Geli Bulgularinin Değerlendirilmesi. **2016**, 17, 37-37

117 Evidence-Based Medicine. **2016**, 137-145

116 Posterior Uveitis. **2016**, 533-543

1

115 Uveitis in the Elderly. **2016**, 633-642

114 Serpiginous Choroiditis. **2016**, 161-168

2

113 Corticosteroids. **2016**, 273-284

1

112 Medical Management of CME Associated with Uveitis. **2017**, 59-75

111 Clinical Syndromes, Classifications, and Differential Diagnosis. **2017**, 61-80

110 Macular Edema. **2017**, 343-354

1

109 Birdshot Retinochoroidopathy. **2017**, 143-147

108 Medical Therapy. **2017**, 301-316

107 Sarcoidosis. **2017**, 243-254

1

106 Ankylosing Spondylitis. **2017**, 135-141

0

105 Medical Therapy Algorithms. **2017**, 109-119

104 Noninfectious Causes. **2017**, 93-105

103 Optical Coherence Tomography Findings of Serpiginous-like Choroiditis in Ocular Tuberculosis and Serpiginous Choroiditis. **2017**, 2, 33-37

102 Recommendations for treatment of non-infectious uveitis. **2018**, 52, 56-63

101 Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan. **2018**, 8, 117-120

1

100 Anterior Granulomatous Uveitis: Differential Diagnosis. **2018**, 1-6

- 99 Immunosuppressives and biologicals in uveitis: The way forward [Current concepts. **2019**, 57, 139 0
- 98 T Cell Inhibitors. **2019**, 45-56
- 97 Multifocal Choroiditis and Panuveitis. **2020**, 29-37 1
- 96 Serpiginous Choroiditis. **2020**, 9-17
- 95 Direct Injection of 5-Fluorouracil Improves Outcomes in Cicatrizing Conjunctival Disorders Secondary to Systemic Disease. **2021**, 37, 145-153 2
- 94 More Than Meets the Eye: A Rare Case of Posterior Scleritis Masquerading as Orbital Cellulitis. **2020**, 12, e8177
- 93 Systemic immunosuppressive therapies for uveitis in developing countries. **2020**, 68, 1852-1862 1
- 92 Intermediate Uveitis. **2020**, 1-32
- 91 Approaches to Medical Therapy. **2020**, 73-102
- 90 Lens Complications in Uveitis. **2020**, 43-59
- 89 Ophthalmic Complications of the Rheumatic Diseases and Anti-Rheumatic Drugs (in Elderly). **2020**, 73-94
- 88 Glaucoma Associated with Disorders of the Retina, Vitreous, and Choroid. **2020**, 1-33
- 87 Biologic Therapies in Sarcoidosis and Uveitis: A Review. **2020**, 12, e9057
- 86 The Effect of Adalimumab on Refractory Uveitis. **2020**, 61, 746-754 0
- 85 The Tip of the Iceberg: Current Knowledge of Uveitis in Juvenile Arthritis. **2005**, 125-139
- 84 Autoimmune Keratitis. **2007**, 77-90 0
- 83 Intraocular Corticosteroid Implants. **2008**, 17-22
- 82 Uveitic Glaucoma. **2009**, 49-58 1

81	A reconsideration of anterior chamber flare and its clinical relevance for children with chronic anterior uveitis (an American Ophthalmological Society thesis). 2007 , 105, 344-64	37
80	A serum- and feeder-free technique of culturing human corneal epithelial stem cells on amniotic membrane. 2009 , 15, 1294-302	25
79	The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis). 2016 , 114, T3	18
78	The use of biologic therapies in uveitis. 2018 , 62, 105-113	4
77	Ophthalmic manifestations of rheumatologic disease: diagnosis and management. 2012 , 109, 53-8	3
76	Intra-vitreous injection of methotrexate in experimental endotoxin-induced uveitis in rabbit. 2018 , 9, 315-321	2
75	Sympathetic Ophthalmia: Where Do We Currently Stand on Treatment Strategies?. 2021 , 15, 4201-4218	
74	Sympathetic Ophthalmia: Where Do We Currently Stand on Treatment Strategies?. 2021 , Volume 15, 4201-4218	0
73	Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspective. 2021 , 6, e000896	0
72	Epidemiology of Uveitis in Olmsted County, Minnesota: A Population-Based Follow-Up Study. 2021 , 1-7	
71	und (engl.: Scleritis; griechisch sklῆρ = spröde, hart). 2021 , 287-306	
70	Hintergrund/therapeutische Grundrezepte. 2021 , 413-471	
69	Recent Potential Treatment Approaches for the Management of Uveitis. 2020 , 094-098	
68	Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study.. 2022 , 12, 3	
67	Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.. 2022 ,	
66	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.. 2022 ,	1
65	Tocilizumab in rheumatoid arthritis-associated peripheral ulcerative keratitis: A case report.	0
64	Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.. 2022 , 66, 130	

63	Outcomes of uveitic macular edema in the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.. 2022,		1
62	The conundrum of clinical trials for the uveitides: appropriate outcome measures for one treatment used in several diseases.. 2022,		0
61	Mycophenolate versus Methotrexate in Non-infectious Ocular Inflammatory Disease: A Systematic Review and Meta-Analysis.. 2022, 1-8		
60	Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study.. 2022, 12, e051378		1
59	Antimetabolite Drugs Exhibit Distinctive Immunomodulatory Mechanisms and Effects on the Intestinal Microbiota in Experimental Autoimmune Uveitis.. 2022, 63, 30		0
58	Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.. 2022, 1		1
57	Therapeutic Effect of Rapamycin-Loaded Small Extracellular Vesicles Derived from Mesenchymal Stem Cells on Experimental Autoimmune Uveitis.. 2022, 13, 864956		1
56	Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy.. <i>American Journal of Ophthalmology,</i> 2022,	4-9	0
55	Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-Analysis.. 2022, 13, 749312		0
54	Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection.. 2021,		2
53	Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications.. 2022, 15, 17562848221085889		0
52	Comment on: Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study.. 2022,		
51	PD-1 Targeted Nanoparticles Inhibit Activated T Cells and Alleviate Autoimmunity via Suppression of Cellular Energy Metabolism Mediated by PKM2.. 2022, 17, 1711-1724		0
50	2', 4'-Dihydroxy-2,3-dimethoxychalcone: A pharmacological inverse agonist of ROR β ameliorating Th17-driven inflammatory diseases by regulating Th17/Treg.. 2022, 108, 108769		0
49	Image_1.JPEG. 2018,		
48	Image_2.JPEG. 2018,		
47	Image_3.JPEG. 2018,		
46	Image_4.JPEG. 2018,		

45 Image_5.JPEG. **2018**,

44 Table_1.docx. **2018**,

43 Diagnostic and Therapeutic Challenges.. **2022**,

42 Sympathetic Ophthalmia. **2022**, 4277-4291

41 Gastrointestinal and Nutritional Disorders. **2022**, 7215-7245

40 Ocular Manifestations of Systemic Vasculitides. **2022**, 7449-7495

39 Intermediate Uveitis. **2022**, 4161-4191

38 Glaucoma Associated with Disorders of the Retina, Vitreous, and Choroid. **2022**, 1807-1839

37 Ocular involvement in rheumatoid arthritis [literature review]. **2022**, 2, 7

36 Pseudophemphigoid after long-term medical glaucoma treatment. **2022**,

35 A serum protein network early predicts the need for systemic immunomodulatory therapy in non-infectious uveitis. **2022**, 100175 ○

34 Sjögren's Syndrome Dry Eye Disease. **2023**, 97-105

33 Topical Ocular Anti-TNF α Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study. **2022**, 11, 14 ○

32 Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study. 1-9

31 Intermediate Uveitis: A Review. 1-20

30 Systemic and Ocular Anti-Inflammatory Mechanisms of Green Tea Extract on Endotoxin-Induced Ocular Inflammation. 13, ○

29 Self-therapeutic metal-based nanoparticles for treating inflammatory diseases. **2022**, 1 ○

28 Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era. **2022**, 11, 4538 ○

- 27 Paediatric Retinal Inflammatory Disorders. **2022**, 57-85 ○
- 26 Adalimumab in Vogt-Koyanagi-Harada disease: A case report. **2022**, 2, 906 ○
- 25 Current Management of Pediatric Uveitis. **2022**, 97-119 ○
- 24 Commentary: Treatment of refractory uveitis with Vogt Koyanagi Harada disease. **2022**, 2, 909 ○
- 23 Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis. ○
- 22 Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study. *bjophthalmol-2021-320770* ○
- 21 A review of patient-reported outcome measures used in uveitis. **2022**, ○
- 20 Bilateral retinal vasculitis associated with cold agglutinin disease treated with obinutuzumab and infliximab. **2022**, 101752 ○
- 19 Novel epigenetic therapy for Th17 cell mediated autoimmune inflammatory diseases. **2022**, 86, 104368 ○
- 18 Treat to target in Behcet's disease: Should we follow the paradigm of other systemic rheumatic diseases?. **2023**, 246, 109186 ○
- 17 Pathogenesis and current therapies for non-infectious uveitis. ○
- 16 Long-term Experience with Anti-tumor Necrosis factor- α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis. 1-8 ○
- 15 Local versus Systemic Therapy for Noninfectious Uveitis (NIU). 1-9 ○
- 14 Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease. 1-7 1
- 13 Diagnosis, Treatment, and Prevention of Noninfectious Acute Anterior Uveitis with or without Human Leukocyte Antigen B27 in Adults - Expert Consensus in Taiwan. 1-8 ○
- 12 Challenges and management of childhood noninfectious chronic uveitis. 1-13 ○
- 11 Tocilizumab for the Management of Glucocorticoid-Refractory Idiopathic Orbital Inflammation. ○
- 10 The incidence, presenting clinical findings and treatment patterns of Birdshot Retinochoroiditis in a high-prevalence region: findings from Northern Ireland, England and Wales. ○

- 9 THE EVALUATION RETINAL TOXICITY OF INTRAVITREAL INFlixIMAB INJECTION. ○
- 8 Overview and update on cytomegalovirus-associated anterior uveitis and glaucoma. 11, ○
- 7 Dual-Energy X-Ray Absorptiometry Scan Utilization and Skeletal Fragility Among Non-Infectious Uveitis Patients Exposed to Oral Glucocorticoids. 1-9 ○
- 6 Effects of Oral 5-Aminolevulinic Acid on Lipopolysaccharide-Induced Ocular Inflammation in Rats. 2023, 10, 207 ○
- 5 Long-lived autoreactive memory CD4 + T cells mediate the sustained retinopathy in chronic autoimmune uveitis. 2023, 37, ○
- 4 Research Status of Marginal CornealUlcer. 2023, 12, 31-37 ○
- 3 Analyzing the demographics of patients with uveitis in an indigent, urban population. 2023, 23, ○
- 2 Noninfectious posterior uveitis. ○
- 1 Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN \square) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months. ○